Research Report on China's OTC Drug Market, 2013-2017
Since OTC drugs are mainly used by consumers without a physician's prescription in treating certain common ailments which are easy for self-diagnosis and self-treatment, the structure of their terminal market is relatively stable. The Top 4 categories of OTC drugs in Chinese market include cough and cold medications and anti-allergic agents, recuperated drugs, vitamins & minerals and tonic drugs as well as febrifuges and painkillers. The features of OTC drugs determine that this industry has low technical barriers and low entrant requirements. As a result, in China, there are many OTC drug manufacturing enterprises, most of which are small and medium enterprises with insufficient capital and non-advanced techniques. Besides, the homogeneity of the products is serious so that it is difficult to establish brand images.
Compared with that of countries with advanced medicine levels, China OTC drug industry is featured by late start, fast growth and huge potential.According to CRI's research, with a CAGR of over 18% during the period from 2000 to 2012, the market scale of China OTC drug industry exceeded CNY 170 billion in 2012.
With the increase in chronic disease incidence rate and residents' healthcare consciousness, consumers purchasing OTC drugs will become a universal phenomenon and its market demand will be continuously expanded. Meanwhile, in order to ease the stress exerted by the shortage of expenditures on healthcare, Chinese government is supposed to put forward new policies to support OTC drug market, to accelerate OTC drug transition, to increase OTC drug market share and to help China OTC drug industry to enter into a stable growing stage.
The OTC drug industry is featured by obvious brand consumption. Therefore, famous brand products occupy the mainstream market, while those less famous brands is difficult to sell. They can only make up market vacancy by virtue of uniqueness or occupy market by regional advantages. With the standardizing development of domestic OTC drug market and the increase in residents' healthcare consciousness, the competition focus will be inevitably conversed from quality and price competition to brand and service competition. The increase in industry brand barrier makes it difficult for generic drug enterprises to build up brand images. There is an obvious trend on industry differentiation. Therefore, brand enterprises will become the biggest beneficiary in expanded OTC market.
With the development of China OTC drug industry, Chinese medicine retail terminal has rapidly risen to the major sales channel of OTC drugs. With drugstores catenation, the bargaining ability of downstream industries has been improved and brand co-operation has become the inevitable choice for the market. Famous brands give great support to the terminal market, while those less famous brands, jointed with the famous brands, make great efforts to coordinate the profit distribution in the entire industry chain so as to leave enough profit-earning opportunities for the retail terminals.
It is predicted by CRI that the switches between Rx and OTC products, the increasing trend of aging population in China and the increase in rural residents' incomes will become the major driving forces for the development of China OTC drug market. It is also estimated by CRI that the CAGR of China OTC drug market scale will maintain above 15%, which indicates that China will become the key OTC drug market in the world.
Through this report, the readers can acquire the following information:
Compared with that of countries with advanced medicine levels, China OTC drug industry is featured by late start, fast growth and huge potential.According to CRI's research, with a CAGR of over 18% during the period from 2000 to 2012, the market scale of China OTC drug industry exceeded CNY 170 billion in 2012.
With the increase in chronic disease incidence rate and residents' healthcare consciousness, consumers purchasing OTC drugs will become a universal phenomenon and its market demand will be continuously expanded. Meanwhile, in order to ease the stress exerted by the shortage of expenditures on healthcare, Chinese government is supposed to put forward new policies to support OTC drug market, to accelerate OTC drug transition, to increase OTC drug market share and to help China OTC drug industry to enter into a stable growing stage.
The OTC drug industry is featured by obvious brand consumption. Therefore, famous brand products occupy the mainstream market, while those less famous brands is difficult to sell. They can only make up market vacancy by virtue of uniqueness or occupy market by regional advantages. With the standardizing development of domestic OTC drug market and the increase in residents' healthcare consciousness, the competition focus will be inevitably conversed from quality and price competition to brand and service competition. The increase in industry brand barrier makes it difficult for generic drug enterprises to build up brand images. There is an obvious trend on industry differentiation. Therefore, brand enterprises will become the biggest beneficiary in expanded OTC market.
With the development of China OTC drug industry, Chinese medicine retail terminal has rapidly risen to the major sales channel of OTC drugs. With drugstores catenation, the bargaining ability of downstream industries has been improved and brand co-operation has become the inevitable choice for the market. Famous brands give great support to the terminal market, while those less famous brands, jointed with the famous brands, make great efforts to coordinate the profit distribution in the entire industry chain so as to leave enough profit-earning opportunities for the retail terminals.
It is predicted by CRI that the switches between Rx and OTC products, the increasing trend of aging population in China and the increase in rural residents' incomes will become the major driving forces for the development of China OTC drug market. It is also estimated by CRI that the CAGR of China OTC drug market scale will maintain above 15%, which indicates that China will become the key OTC drug market in the world.
Through this report, the readers can acquire the following information:
- Current Development Status of China OTC Drug Industry
- Development Environment of China OTC Drug Industry
- Market Competition Status of China OTC Drug Industry
- Key OTC Drug Manufacturing Enterprises in China
- Development Prospect and Potential Investment Opportunity in China OTC Drug Market
- Pharmaceutical Enterprises
- Medicine Trade Enterprises/Hospitals
- Investors, Research Institutes and Government Departments Concerned about OTC Drug Market
1 BASIC CONCEPT OF OTC DRUGS
1.2 Differences Between OTC Drugs and Rx Drugs
1.3 Development Progress of the OTC Drug Industry
1.4 Features of OTC Drugs
1.4.1 High Flexibility
1.4.2 Technical Features of the OTC Drug Industry
1.4.3 Preference for Brand Consumption
2 ANALYSES ON THE OTC DRUG INDUSTRY IN CHINA, 2013-2017
2.1 Overview on Varieties of OTC Drugs
2.2 Market Scale
2.3 Overview on OTC Drug Manufacturing Enterprises
3 MARKET COMPETITION STATUS OF CHINA OTC DRUG INDUSTRY, 2008-2012
3.1 Industry Competition Status
3.2 Downstream Industry
3.3 Potential Entrants
4 ANALYSES ON KEY OTC DRUG MANUFACTURING ENTERPRISES IN CHINA
4.1 Harbin Pharmaceutical Group Co., Ltd
4.2 Huarun Sanjiu Medical & Pharmaceutical Co., Ltd
4.3 Renhe (Group) Development Co., Ltd
4.4 Xi'an-Janssen Pharmaceutical Co., Ltd
4.5 Wyeth Pharmaceutical Co., Ltd
4.6 Yangtze River Pharmaceutical Group
4.7 Tianjin SK&F Pharmaceutical Co., Ltd
4.8 Yunnan Baiyao Group Co., Ltd
4.9 Jiangzhong Pharmaceutical Co., Ltd
4.10 Zhejiang Conba Pharmaceutical Co., Ltd
5 FORECASTS ON THE DEVELOPMENT OF CHINA OTC DRUG INDUSTRY, 2013-2017
5.1 Conversion of Varieties Promote the Growth of the OTC Drug Industry
5.2 Increasing Incidence Rate of Chronic Diseases Boosts the Market Demand
5.3 Increasing Healthcare Consciousness of Chinese Residents Promotes OTC Drug Market Development
5.4 Accelerating Urbanization Process Enlarges OTC Drug Market Scale
5.5 Forecast on OTC Drug Market Scale, 2013-2017
5.6 Recommendations on the Investment and Development
1.2 Differences Between OTC Drugs and Rx Drugs
1.3 Development Progress of the OTC Drug Industry
1.4 Features of OTC Drugs
1.4.1 High Flexibility
1.4.2 Technical Features of the OTC Drug Industry
1.4.3 Preference for Brand Consumption
2 ANALYSES ON THE OTC DRUG INDUSTRY IN CHINA, 2013-2017
2.1 Overview on Varieties of OTC Drugs
2.2 Market Scale
2.3 Overview on OTC Drug Manufacturing Enterprises
3 MARKET COMPETITION STATUS OF CHINA OTC DRUG INDUSTRY, 2008-2012
3.1 Industry Competition Status
3.2 Downstream Industry
3.3 Potential Entrants
4 ANALYSES ON KEY OTC DRUG MANUFACTURING ENTERPRISES IN CHINA
4.1 Harbin Pharmaceutical Group Co., Ltd
4.2 Huarun Sanjiu Medical & Pharmaceutical Co., Ltd
4.3 Renhe (Group) Development Co., Ltd
4.4 Xi'an-Janssen Pharmaceutical Co., Ltd
4.5 Wyeth Pharmaceutical Co., Ltd
4.6 Yangtze River Pharmaceutical Group
4.7 Tianjin SK&F Pharmaceutical Co., Ltd
4.8 Yunnan Baiyao Group Co., Ltd
4.9 Jiangzhong Pharmaceutical Co., Ltd
4.10 Zhejiang Conba Pharmaceutical Co., Ltd
5 FORECASTS ON THE DEVELOPMENT OF CHINA OTC DRUG INDUSTRY, 2013-2017
5.1 Conversion of Varieties Promote the Growth of the OTC Drug Industry
5.2 Increasing Incidence Rate of Chronic Diseases Boosts the Market Demand
5.3 Increasing Healthcare Consciousness of Chinese Residents Promotes OTC Drug Market Development
5.4 Accelerating Urbanization Process Enlarges OTC Drug Market Scale
5.5 Forecast on OTC Drug Market Scale, 2013-2017
5.6 Recommendations on the Investment and Development
SELECTED CHARTS
Chart Differences Between Rx Drug and OTC Drug
Chart Category Management of Drugs in Some Countries
Chart Advertising Restrictions on Drugs in Some Countries
Chart Expansion Status of OTC Drug Catalog in China
Chart Market Scale of OTC Drugs in China, 2008-2012
Chart Proportion of OTC Drug Sales in the Total Drug Sales in China, 2008-2012
Chart Ranking of China OTC Drug Manufacturing Enterprises in 2012
Chart Chain Drugstores with Private Brands or Higher Proportion of High Gross Profit Products
Chart Chain Drugstores with Private Brands or Lower Proportion of High Gross Profit Products
Chart Newly-added OTC Drugs in China After Restarting Evaluation Work
Chart Number of Chinese Aged People (65 years old and above)
Chart Healthcare Expenditure Per Capita of Urban and Rural Residents in China, 2001-2011
Chart Population Urbanization Rate in China, 2001-2012
Chart Forecast on China OTC Drug Market Scale, 2013-2017
Chart Differences Between Rx Drug and OTC Drug
Chart Category Management of Drugs in Some Countries
Chart Advertising Restrictions on Drugs in Some Countries
Chart Expansion Status of OTC Drug Catalog in China
Chart Market Scale of OTC Drugs in China, 2008-2012
Chart Proportion of OTC Drug Sales in the Total Drug Sales in China, 2008-2012
Chart Ranking of China OTC Drug Manufacturing Enterprises in 2012
Chart Chain Drugstores with Private Brands or Higher Proportion of High Gross Profit Products
Chart Chain Drugstores with Private Brands or Lower Proportion of High Gross Profit Products
Chart Newly-added OTC Drugs in China After Restarting Evaluation Work
Chart Number of Chinese Aged People (65 years old and above)
Chart Healthcare Expenditure Per Capita of Urban and Rural Residents in China, 2001-2011
Chart Population Urbanization Rate in China, 2001-2012
Chart Forecast on China OTC Drug Market Scale, 2013-2017
